Inherited bleeding disorder, platelet-type
MONDO:0000009Also known as: blood platelet disease, platelet disorder, bleeding disorder, platelet-type, thrombocytopathy
32 clinical trials for this condition and its sub-types, 6 tagged with Inherited bleeding disorder, platelet-type itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Inherited bleeding disorder, platelet-type
-
Glanzmann thrombasthenia 8 trials
2 sub-types
- Glanzmann thrombasthenia 1 7 trials
- Glanzmann thrombasthenia 2 0 trials
-
Platelet-type bleeding disorder 10 8 trials
-
Bernard-Soulier syndrome 0 trials
1 sub-type
-
Quebec platelet disorder 0 trials
-
Scott syndrome 0 trials
-
Bleeding disorder, platelet-type, 21 0 trials
-
Bleeding disorder, platelet-type, 22 0 trials
-
Bleeding disorder, platelet-type, 24 0 trials
-
Bleeding disorder, platelet-type, 25 0 trials
-
Gray platelet syndrome 0 trials
-
Platelet-type bleeding disorder 11 0 trials
-
Platelet-type bleeding disorder 12 0 trials
-
Platelet-type bleeding disorder 14 0 trials
-
Platelet-type bleeding disorder 15 0 trials
-
Platelet-type bleeding disorder 16 0 trials
-
Platelet-type bleeding disorder 17 0 trials
-
Platelet-type bleeding disorder 18 0 trials
-
Platelet-type bleeding disorder 19 0 trials
-
Platelet-type bleeding disorder 20 0 trials
-
Platelet-type bleeding disorder 8 0 trials
-
Platelet-type bleeding disorder 9 0 trials
-
Platelet-type von Willebrand disease 0 trials
-
New drug combo aims to supercharge weight loss in obesity trial
Disease control OngoingThis phase 2 study tests two drugs, bimagrumab and tirzepatide, alone or together, to see if they help adults with obesity or overweight lose weight safely. About 252 participants without type 2 diabetes will take the drugs or a placebo for up to 70 weeks. The main goal is to mea…
Phase 2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New enzyme replacement therapy aims to stop dangerous blood clots in rare disease
Disease control OngoingThis study tests a medicine called TAK-755 in people with a rare inherited blood disorder called congenital thrombotic thrombocytopenic purpura (cTTP). The condition causes dangerous blood clots and bleeding. TAK-755 replaces a missing enzyme to help prevent or treat these episod…
Phase 3 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New antibody aims to stop bleeding episodes in rare clotting disorder
Disease control OngoingThis early-phase trial tests an experimental antibody called HMB-001 in 57 adults with Glanzmann thrombasthenia, a rare bleeding disorder. The study aims to see if the drug is safe and can reduce the number and severity of bleeds when given regularly. Participants receive single …
Phase 1/2 • Sponsor: Hemab ApS • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Weight-Loss drug combo study pulled before starting
Disease control CancelledThis study aimed to test two drugs, bimagrumab and tirzepatide, alone or together, for helping adults with obesity or overweight and type 2 diabetes lose weight. It was planned for about 13 months but was withdrawn before enrolling any participants. The main goal was to see how m…
Phase 2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC